We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ontozry

News List

Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy pharmatimes
February 09, 2022
Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy.
Ontozry scores MHRA authorisation for focal-onset seizures pharmatimes
June 18, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Arvelle Therapeutics’ Ontozry a marketing authorisation (MA) for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation.
EC approval for Ontozry pharmatimes
April 07, 2021
Angelini Pharma has announced European Commission (EC) approval for anti-seizure drug Ontozry (cenobamate).
Kesimpta and Vazkepa among latest CHMP recommendations pharmatimes
February 01, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval in its latest meeting.